King's College London

Research portal

Residual enhancing disease after surgery for glioblastoma: Evaluation of practice in the United Kingdom

Research output: Contribution to journalArticle

Standard

Residual enhancing disease after surgery for glioblastoma : Evaluation of practice in the United Kingdom. / Ma, Ruichong; Chari, Aswin; Brennan, Paul M.; Alalade, Andrew; Anderson, Ian; Solth, Anna; Marcus, Hani J.; Watts, Colin; British Neurosurgical Trainee Research Collaborative; Kolias, Angelos; Sinha, Rohit; O'Neill, Kevin; Rasul, Fahid; Ashkan, Keyoumars; Paine, Heidi; Corns, Robert; Jenkinson, Michael; Kitchen, Neil; Holliman, Damian; Glancz, Laurence; Aly, Ahmed; Smith, Stuart; Plaha, Puneet; Dyson, Edward; Toescu, Sebastian; Haliasos, Nick; Ghosh, Arnab; McKintosh, Edward; Rominiyi, Olamide; Jellinek, David; Gallagher, Mat; Jones, Tim; Wykes, Victoria; Grundy, Paul; Haq, Imran; Brydon, Howard.

In: Neuro-Oncology Practice, Vol. 5, No. 2, 06.2018, p. 74-81.

Research output: Contribution to journalArticle

Harvard

Ma, R, Chari, A, Brennan, PM, Alalade, A, Anderson, I, Solth, A, Marcus, HJ, Watts, C, British Neurosurgical Trainee Research Collaborative, Kolias, A, Sinha, R, O'Neill, K, Rasul, F, Ashkan, K, Paine, H, Corns, R, Jenkinson, M, Kitchen, N, Holliman, D, Glancz, L, Aly, A, Smith, S, Plaha, P, Dyson, E, Toescu, S, Haliasos, N, Ghosh, A, McKintosh, E, Rominiyi, O, Jellinek, D, Gallagher, M, Jones, T, Wykes, V, Grundy, P, Haq, I & Brydon, H 2018, 'Residual enhancing disease after surgery for glioblastoma: Evaluation of practice in the United Kingdom', Neuro-Oncology Practice, vol. 5, no. 2, pp. 74-81. https://doi.org/10.1093/nop/npx023

APA

Ma, R., Chari, A., Brennan, P. M., Alalade, A., Anderson, I., Solth, A., Marcus, H. J., Watts, C., British Neurosurgical Trainee Research Collaborative, Kolias, A., Sinha, R., O'Neill, K., Rasul, F., Ashkan, K., Paine, H., Corns, R., Jenkinson, M., Kitchen, N., Holliman, D., ... Brydon, H. (2018). Residual enhancing disease after surgery for glioblastoma: Evaluation of practice in the United Kingdom. Neuro-Oncology Practice, 5(2), 74-81. https://doi.org/10.1093/nop/npx023

Vancouver

Ma R, Chari A, Brennan PM, Alalade A, Anderson I, Solth A et al. Residual enhancing disease after surgery for glioblastoma: Evaluation of practice in the United Kingdom. Neuro-Oncology Practice. 2018 Jun;5(2):74-81. https://doi.org/10.1093/nop/npx023

Author

Ma, Ruichong ; Chari, Aswin ; Brennan, Paul M. ; Alalade, Andrew ; Anderson, Ian ; Solth, Anna ; Marcus, Hani J. ; Watts, Colin ; British Neurosurgical Trainee Research Collaborative ; Kolias, Angelos ; Sinha, Rohit ; O'Neill, Kevin ; Rasul, Fahid ; Ashkan, Keyoumars ; Paine, Heidi ; Corns, Robert ; Jenkinson, Michael ; Kitchen, Neil ; Holliman, Damian ; Glancz, Laurence ; Aly, Ahmed ; Smith, Stuart ; Plaha, Puneet ; Dyson, Edward ; Toescu, Sebastian ; Haliasos, Nick ; Ghosh, Arnab ; McKintosh, Edward ; Rominiyi, Olamide ; Jellinek, David ; Gallagher, Mat ; Jones, Tim ; Wykes, Victoria ; Grundy, Paul ; Haq, Imran ; Brydon, Howard. / Residual enhancing disease after surgery for glioblastoma : Evaluation of practice in the United Kingdom. In: Neuro-Oncology Practice. 2018 ; Vol. 5, No. 2. pp. 74-81.

Bibtex Download

@article{004a8c4eea204896912ed705b890f8ee,
title = "Residual enhancing disease after surgery for glioblastoma: Evaluation of practice in the United Kingdom",
abstract = "Background: A growing body of clinical data highlights the prognostic importance of achieving gross total resection (GTR) in patients with glioblastoma. The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease. Methods: The study was in 2 parts: an electronic questionnaire sent to United Kingdom neuro-oncology surgeons to assess surgical practice followed by a 3-month prospective, multicenter observational study of current neurosurgical oncology practice. Results: Twenty-seven surgeons representing 22 neurosurgical units completed the questionnaire. Prospective data were collected for 113 patients from 15 neurosurgical units. GTR was deemed to be achieved at time of surgery in 82% (91/111) of cases, but in only 45% (36/80) on postoperative MRI. Residual enhancing disease was deemed operable in 16.3% (13/80) of cases, however, no patient underwent early repeat surgery for residual enhancing disease. The most commonly cited reason (38.5%, 5/13) was perceived lack of clinical benefit. Conclusion: There is a subset of patients for whom GTR is thought possible, but not achieved at surgery. For these patients, early repeat resection may improve overall survival. Further prospective surgical research is required to better define the prognostic implications of GTR for residual enhancing disease and examine the potential benefit of this early re-intervention.",
keywords = "Glioblastoma, Glioma surgery, Neurooncology, Residual enhancing disease, Survival",
author = "Ruichong Ma and Aswin Chari and Brennan, {Paul M.} and Andrew Alalade and Ian Anderson and Anna Solth and Marcus, {Hani J.} and Colin Watts and {British Neurosurgical Trainee Research Collaborative} and Angelos Kolias and Rohit Sinha and Kevin O'Neill and Fahid Rasul and Keyoumars Ashkan and Heidi Paine and Robert Corns and Michael Jenkinson and Neil Kitchen and Damian Holliman and Laurence Glancz and Ahmed Aly and Stuart Smith and Puneet Plaha and Edward Dyson and Sebastian Toescu and Nick Haliasos and Arnab Ghosh and Edward McKintosh and Olamide Rominiyi and David Jellinek and Mat Gallagher and Tim Jones and Victoria Wykes and Paul Grundy and Imran Haq and Howard Brydon",
year = "2018",
month = jun,
doi = "10.1093/nop/npx023",
language = "English",
volume = "5",
pages = "74--81",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "2",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Residual enhancing disease after surgery for glioblastoma

T2 - Evaluation of practice in the United Kingdom

AU - Ma, Ruichong

AU - Chari, Aswin

AU - Brennan, Paul M.

AU - Alalade, Andrew

AU - Anderson, Ian

AU - Solth, Anna

AU - Marcus, Hani J.

AU - Watts, Colin

AU - British Neurosurgical Trainee Research Collaborative

AU - Kolias, Angelos

AU - Sinha, Rohit

AU - O'Neill, Kevin

AU - Rasul, Fahid

AU - Ashkan, Keyoumars

AU - Paine, Heidi

AU - Corns, Robert

AU - Jenkinson, Michael

AU - Kitchen, Neil

AU - Holliman, Damian

AU - Glancz, Laurence

AU - Aly, Ahmed

AU - Smith, Stuart

AU - Plaha, Puneet

AU - Dyson, Edward

AU - Toescu, Sebastian

AU - Haliasos, Nick

AU - Ghosh, Arnab

AU - McKintosh, Edward

AU - Rominiyi, Olamide

AU - Jellinek, David

AU - Gallagher, Mat

AU - Jones, Tim

AU - Wykes, Victoria

AU - Grundy, Paul

AU - Haq, Imran

AU - Brydon, Howard

PY - 2018/6

Y1 - 2018/6

N2 - Background: A growing body of clinical data highlights the prognostic importance of achieving gross total resection (GTR) in patients with glioblastoma. The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease. Methods: The study was in 2 parts: an electronic questionnaire sent to United Kingdom neuro-oncology surgeons to assess surgical practice followed by a 3-month prospective, multicenter observational study of current neurosurgical oncology practice. Results: Twenty-seven surgeons representing 22 neurosurgical units completed the questionnaire. Prospective data were collected for 113 patients from 15 neurosurgical units. GTR was deemed to be achieved at time of surgery in 82% (91/111) of cases, but in only 45% (36/80) on postoperative MRI. Residual enhancing disease was deemed operable in 16.3% (13/80) of cases, however, no patient underwent early repeat surgery for residual enhancing disease. The most commonly cited reason (38.5%, 5/13) was perceived lack of clinical benefit. Conclusion: There is a subset of patients for whom GTR is thought possible, but not achieved at surgery. For these patients, early repeat resection may improve overall survival. Further prospective surgical research is required to better define the prognostic implications of GTR for residual enhancing disease and examine the potential benefit of this early re-intervention.

AB - Background: A growing body of clinical data highlights the prognostic importance of achieving gross total resection (GTR) in patients with glioblastoma. The aim of this study was to determine nationwide practice and attitudes towards achieving GTR and dealing with residual enhancing disease. Methods: The study was in 2 parts: an electronic questionnaire sent to United Kingdom neuro-oncology surgeons to assess surgical practice followed by a 3-month prospective, multicenter observational study of current neurosurgical oncology practice. Results: Twenty-seven surgeons representing 22 neurosurgical units completed the questionnaire. Prospective data were collected for 113 patients from 15 neurosurgical units. GTR was deemed to be achieved at time of surgery in 82% (91/111) of cases, but in only 45% (36/80) on postoperative MRI. Residual enhancing disease was deemed operable in 16.3% (13/80) of cases, however, no patient underwent early repeat surgery for residual enhancing disease. The most commonly cited reason (38.5%, 5/13) was perceived lack of clinical benefit. Conclusion: There is a subset of patients for whom GTR is thought possible, but not achieved at surgery. For these patients, early repeat resection may improve overall survival. Further prospective surgical research is required to better define the prognostic implications of GTR for residual enhancing disease and examine the potential benefit of this early re-intervention.

KW - Glioblastoma

KW - Glioma surgery

KW - Neurooncology

KW - Residual enhancing disease

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85038885056&partnerID=8YFLogxK

U2 - 10.1093/nop/npx023

DO - 10.1093/nop/npx023

M3 - Article

AN - SCOPUS:85038885056

VL - 5

SP - 74

EP - 81

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 2

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454